AlpalifeBio provides customized service for nanobody drug R&D at various stages, such as nanobody/VHH discovery, humanization, affinity maturation and cell-based functional study. We also provide customized services including GPCR expression and purification,structural determination and functional study.

Our company has a laboratory area of 28,000 sq. ft. with more than one hundred employees led by senior scientists. Our company uses a camelid nanobody discovery platform to provide services such as antigen preparation, immunization, phage library construction and screening for VHH nanobody drug candidates with high affinity and specificity.

AlpalifeBio  has successfully discovered  hundreds of therapeutic nanobody/VHH candidates with high affinity and specificity against various antigens for our customers at top biopharma companies in United States, Germany, Belgium, Australia, China, Japan, Thailand, South Korea, etc.